Novo cuts Wegovy list price to $349

Novo Nordisk said Monday it reduced the list price for higher-dose Wegovy to $349/month (from $499) for cash‑paying patients and launched a temporary $199/month offer for the first two months of low‑dose Wegovy and Ozempic, aligning with a recent federal drug‑pricing framework. The price changes apply nationwide via pharmacies, home delivery and some telemedicine providers; clinicians and surveys still cite affordability challenges for patients without insurance.